Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc. Common Stock (ACRV) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ACRV · as of Sep 30, 2025
Ownership Breakdown
47
Institutional Holders
▼ 5 vs Q2
$32.67M
Total Inst. Value
▲ $11.48M vs Q2
31.56M
Shares Outstanding
freeFloat 70.37%
17.52M
13F Shares Held
▼ 279,546 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ACRV largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. pharmaceutical preparations | 8.34M | 21.69% | 21.69% | $15.10B | Nov 14, 2025 | — held |
SANDS CAPITAL VENTURES, LLC pharmaceutical preparations | 2.12M | 5.52% | 5.52% | $3.84B | Nov 13, 2025 | — held |
CITADEL ADVISORS LLC pharmaceutical preparations | 1.54M | 4.01% | 4.01% | $2.79B | Nov 14, 2025 | ▼ 354.2K |
WELLINGTON MANAGEMENT GROUP LLP pharmaceutical preparations | 888.1K | 2.31% | 2.31% | $1.61B | Nov 14, 2025 | — held |
UBS GROUP AG pharmaceutical preparations | 683.2K | 1.78% | 1.78% | $1.24B | Nov 13, 2025 | ▲ 682.8K |
VANGUARD GROUP INC pharmaceutical preparations | 626.1K | 1.63% | 1.63% | $1.13B | Nov 7, 2025 | ▲ 32.9K |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 623.4K | 1.62% | 1.62% | $1.13B | Nov 13, 2025 | ▲ 114.1K |
ACORN CAPITAL ADVISORS, LLC pharmaceutical preparations | 405.2K | 1.05% | 1.05% | $733.48M | Nov 17, 2025 | — held |
BLACKROCK, INC. pharmaceutical preparations | 331.0K | 86.05% | 86.05% | $599.03M | Nov 12, 2025 | ▼ 76.7K |
TWO SIGMA INVESTMENTS, LP pharmaceutical preparations | 319.2K | 82.99% | 82.99% | $577.76M | Nov 14, 2025 | ▲ 138.0K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
12
Increased
+1.11M shares5
New Positions
first time holders18
Decreased
−868.8K shares3
Sold Out
fully exitedNet shares change (top 50)
+242.9K
+1.11M / −868.8K
Net new holders
-4
5 new / 3 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ACRV insider trading · insider activity
Source: SEC Form 4
16
Buy transactions
7
Sell transactions
2.29
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Blume-Jensen Peter President and CEO | May 21, 2026 | Tax Withhold | 13,729 | $1.79 | $24.6K | 2.25M | Form 4 ↗ |
RA CAPITAL MANAGEMENT, L.P.
| May 18, 2026 | Award | 9,366 | — | — | 9.4K | Form 4 ↗ |
TOMSICEK MICHAEL JOHN director | May 18, 2026 | Award | 9,366 | — | — | 9.4K | Form 4 ↗ |
Shacham Sharon director | May 18, 2026 | Award | 9,366 | — | — | 9.4K | Form 4 ↗ |
Palani Santhosh director | May 18, 2026 | Award | 9,366 | — | — | 9.4K | Form 4 ↗ |
Magovcevic-Liebisch Ivana director | May 18, 2026 | Award | 9,366 | — | — | 9.4K | Form 4 ↗ |
DiRocco Derek director | May 18, 2026 | Award | 9,366 | — | — | 9.4K | Form 4 ↗ |
BAUM CHARLES M director | May 18, 2026 | Award | 9,366 | — | — | 9.4K | Form 4 ↗ |
Peterson Katharine Chief Accounting Officer | May 18, 2026 | Award | 14,227 | — | — | 18.1K | Form 4 ↗ |
Mirza Mansoor Raza Chief Medical Officer | May 18, 2026 | Award | 38,817 | — | — | 38.8K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Acrivon Therapeutics, Inc. Common Stock (ACRV) is primarily owned by institutional investors, who hold approximately 55.5% of total shares outstanding. Company insiders own approximately 29.63%, while retail and public investors account for the remaining 14.84%.
The largest institutional shareholder of Acrivon Therapeutics, Inc. Common Stock is RA CAPITAL MANAGEMENT, L.P., holding approximately 8.34 million shares — equal to 21.69% of outstanding shares — as of September 30, 2025.
A total of 47 institutional investors currently hold ACRV stock, with a combined institutional value of approximately $32,667,899 as of the most recent 13F filing period.
Frequently asked questions
ACRV ownershipAcrivon Therapeutics, Inc. Common Stock (ACRV) is primarily owned by institutional investors, who hold approximately 55.5% of shares. The largest shareholder is RA CAPITAL MANAGEMENT, L.P. with a 21.69% stake. Company insiders hold 29.63%. Data sourced from SEC Form 13F as of September 30, 2025.